Upgrade to SI Premium - Free Trial

Vanda Pharmaceuticals (VNDA) PT Lowered to $21 at Oppenheimer

February 14, 2019 8:10 AM
Oppenheimer analyst Esther Rajavelu lowered the price target on Vanda Pharmaceuticals (NASDAQ: VNDA) to $21.00 (from $29.00) while maintaining a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst EPS View Analyst PT Change

Next Articles